N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents

Journal of Medicinal Chemistry

Volumn 41, Issue 25, 1998, Pages 5020-5036

  Henke, Brad R ^a   Blanchard, Steven G ^a   Brackeen, Marcus F ^a,b   Brown, Kathleen K ^a   Cobb, Jeff E ^a   Collins, Jon L ^a   Harrington Jr , W Wallace ^a   Hashim, Mir A ^a   Hull Ryde, Emily A ^a   Kaldor, Istvan ^a   Kliewer, Steven A ^a   Lake, Debra H ^a   Leesnitzer, Lisa M ^a   Lehmann, Jürgen M ^a   Lenhard, James M ^a   Orband Miller, Lisa A ^a   Miller, John F ^a   Mook Jr , Robert A ^a   Noble, Stewart A ^a,c   Oliver Jr , William ^a   Parks, Derek J ^a   Plunket, Kelli D ^a   Szewczyk, Jerzy R ^a   Willson, Timothy M ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b MonomerChem Inc   (United States)

^c H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 BENZOYLPHENYL)AMINO] 3 [4 (BENZYLOXY)PHENYL]PROPIONIC ACID; 3 [4 (BENZYLOXY)PHENYL] 2 [(1 METHYL 3 OXO 3 PHENYLPROPENYL)AMINO]PROPIONIC ACID; 3 [4 [2 (BENZOXAZOL 2 YLMETHYLAMINO)ETHOXY]PHENYL] [(2 BENZOYLPHENYL)AMINO]PROPIONIC ACID; [(2 BENZOYLPHENYL)AMINO] 3 [4 [2 (5 METHYL 2 PHENYLOXAZOL 4 YL)ETHOXY]PHENYL]PROPIONIC ACID; [(2 BENZOYLPHENYL)AMINO] 3 [4 [2 (METHYLPYRIDIN 2 YLAMINO)ETHOXY]PHENYL]PROPIONIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; N (2 BENZOYLPHENYL) TYROSINE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE HOMEOSTASIS; LIPID METABOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DNA-BINDING PROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; LIPIDS; MALE; MICE; OXAZOLES; PROPIONIC ACIDS; RADIOLIGAND ASSAY; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT FUSION PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; TRANSFECTION; TYROSINE;

EID: 7844224790     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9804127     Document Type: Article

References (89)

1. Greene, M. E.; Blumberg, B.; McBride, O. W.; Yi, H. F.; Kronquist, K.; Kwan, K.; Hsieh, L.; Greene, G.; Nimer, S. D. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Express. 1995, 4, 281-99.
2. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-50.
3. Kliewer, S. A.; Forman, B. M.; Blumberg, B.; Ong, E. S.; Borgmeyer, U.; Mangelsdorf, D. J.; Umesono, K.; Evans, R. M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7355-9.
4. Schmidt, A.; Endo, N.; Rutledge, S. J.; Vogel, R.; Shinar, D.; Rodan, G. A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. 1992, 6, 1634-41.
5. Zhu, Y.; Alvares, K.; Huang, Q.; Rao, M. S.; Reddy, J. K. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem. 1993, 268, 26817-20.
6. Tontonoz, P.; Hu, E.; Graves, R. A.; Budavari, A. I.; Spiegelman, B. M. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994, 8, 1224-34.
7. Tontonoz, P.; Hu, E.; Devine, J.; Beale, E. G.; Spiegelman B. M. PPAR-γ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 1995, 15, 351-7.
8. Schoonjans, K.; Watanabe, M.; Suzuki, H.; Mahfoudi, A.; Krey, G.; Wahli, W.; Grimaldi, P.; Staels, B.; Yamamoto, T.; Auwerx, J. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 1995, 270, 19269-76.
9. Schoonjans, K.; Peinado-Onsurbe, J.; Lefebvre, A.-M.; Heyman, R. A.; Briggs, M.; Deeb, S.; Staels, B.; Auwerx, J. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996, 15, 5336-48.
10. Schoonjans, K.; Martin, G.; Staels, B.; Auwerx, J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 1997, 8, 159-66.
11. Willson, T. M.; Wahli, W. Peroxisome proliferator-activated receptor agonists. Curr. Opin. Chem. Biol. 1997, 1, 235-41.
12. Staels, B.; Schoonjans, K.; Fruchart, J. C.; Auwerx, J. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs) Biochimie 1997, 79, 95-9.
13. Mandrup, S.; Lane, M. D. Regulating adipogenesis. J. Biol. Chem. 1997, 272, 5367-70.
14. Latruffe, N.; Vamecq, J. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Biochimie 1997, 79, 81-94.
15. Devchand, P. R.; Wahli, W. PPARα: tempting fate with fat. Horm. Signaling 1998, 1, 235-56.
16. Chawla, A.; Schwarz, E. J.; Dimaculangan, D. D.; Lazar, M. A. Peroxisome proliferator-activated receptor (PPAR)γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994, 135, 798-800.
17. Tontonoz, P.; Hu, E.; Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994, 79, 1147-56.
18. Fajas, L.; Auboeuf, D.; Raspe, E.; Schoonjans, K; Lefebvre, A.-M.; Saladin, R.; Najib, J.; Laville, M.; Fruchart, J.-C.; Deeb, S.; Vidal-Puig, A.; Flier, J.; Briggs, M. R.; Staels, B.; Vidal, H.; Auwerx, J. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 1997, 272, 18779-789.
19. Xue, J.-C.; Schwarz, E. J.; Chawla, A.; Lazar, M. A. Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARγ. Mol. Cell. Biol. 1996, 16, 1567-75.
20. Yu, K.; Bayona, W.; Kallne, C. B.; Harding, H. P.; Ravera, C. P.; McMahon, G.; Brown, M.; Lazar, M. A. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 1995, 270, 23975-83.
21. Kliewer, S. A.; Lenhard, J. M.; Willson, T. M.; Patel, I.; Morris, D. C.; Lehmann, J. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995, 83, 813-9.
22. Forman, B. M.; Tontonoz, P.; Chen, J.; Brun, R. P.; Spiegelman, B. M.; Evans, R. M. 15-Deoxy-Δ2,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995, 83, 803-12.
23. Krey, G.; Braissant, O.; L'Horset, F.; Kalkhoven, E.; Perroud, M.; Parker, M. G.; Wahli, W. Fatty acids eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 1997, 11, 779-91.
24. Ricote, M.; Li, A. C.; Willson, T. M.; Kelly, C. J.; Glass, C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998, 391, 79-82.
25. Lehmann, J. M.; Moore, L. B.; Simth-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 1995, 270, 12953-6.
26. Lambe, K. G.; Tugwood, J. D. A human peroxisome-proliferator-activated receptor-γ is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur. J. Biochem. 1996, 239, 1-7.
27. Berger, J.; Bailey, P.; Biswas, C.; Cullinan, C. A.; Doebber, T. W.; Hayes, N. S.; Saperstein, R.; Smith, R. G.; Leibowitz, M. D. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996, 137, 4189-95.
28. Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliewer, S. A.; Lehmann, J. M. The Structure-Activity Relationship between Peroxisome Proliferator-Activated Receptor γ. Agonism and the Anti-Hyperglycemic Activity of Thiazolidinediones. J. Med. Chem. 1996, 39, 665-8.
29. Spencer, C. M.; Markham, A. Troglitazone. Drugs 1997, 54, 89-101.
30. Grossman, S. L.; Lessem, J. Mechanisms and clinical effects of thiazolidinediones. Exp. Opin. Invest. Drugs 1997, 6, 1025-40.
31. Leutenegger, M.; Sacca, L.; Alderton, C.; Eckland, D.; Lettis, S. Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non-insulin-dependent diabetes mellitus. Curr. Ther. Res. 1997, 58, 403-416.
32. Levin, K.; Thye-Roenn, P.; Foot, E.; Beck-Nielsen, H. Metabolic effects of troglitazone in NIDDM patients. Endocrinol. Metab. 1997, 4, 255-64.
33. Sironi, A. M.; Vichi, S.; Gastaldelli, A.; Pecori, N.; Anichini, R.; Foot, E.; Seghieri, G.; Ferrannini, E. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with noninsulin-dependent diabetes. Clin. Pharmacol. Ther. 1997, 62, 194-202.
34. Fujiwara, T.; Yoshioka, S.; Yoshioka, T.; Ushiyama, I.; Horikoshi, H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988, 37, 1549-58.
35. Chaiken, R. L.; Eckert-Norton, M.; Pasmantier, R.; Boden, G.; Ryan, I.; Gelfand, R. A.; Lebovitz, H. E. Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia 1995, 38, 1307-12.
36. Colca, J. R.; Morton, D. R. In Antihyperglycemic thiazolidinediones: ciglitazone and its analogues; Colca, J. R., Morton, D. R., Eds.; Smith-Gordon: New York, 1990; pp 255-261.
37. Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem. 1989, 32, 421-8.
38. Ikeda, H.; Taketomi, S.; Sugiyama, Y.; Shimura, Y.; Sohda, T.; Meguro, K.; Fujita, T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim.-Forsch. 1990, 40, 156-62.
39. Sohda, T.; Momose, Y.; Meguro, K.; Kawamatsu, Y.; Sugiyama, Y.; Ikeda, H. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneim.-Forsch. 1990, 40, 37-42.
40. Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull. 1991, 39, 1440-5.
41. Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem. 1994, 37, 3977-85.
42. Cantello, B. C. C.; Cawthorne, M. A.; Haigh, D.; Hindley, R. M.; Smith, S. A.; Thurlby, P. The synthesis of BRL 49653 - a novel and potent antihyperglycemic agent. Bioorg. Med. Chem. Lett. 1994, 4, 1181-4.
43. Horikoshi, H.; Yoshioka, T.; Kawasaki, T.; Nakamura, K.-i.; Matsunuma, N.; Yamaguchi, K.; Sasahara, K. Troglitazone (CS-045), a New Antidiabetic Drug. Anna. Rep. Sankyo Res. Lab. 1994, 46, 1-57.
44. Fujiwara, T.; Yoshioka, S.; Yoshioka, T.; Ushiyama, I.; Horikoshi, H. Characterization of New Oral Antidiabetic Agent CS-045. Diabetes 1988, 37, 1549-58.
45. Henry, R. R. Thiazolidinediones. Endocrinol. Metab. Clin. North Am. 1997, 26, 553-73.
46. Sohda, T.; Mizuno, K.; Kawamatsu, Y. Studies on antidiabetic agents. VI. Asymmetric transformation of (±)-5-[4-(1-methylcyclohexylmethoxy)benzyl]-2,4- thiazolidinedione(ciglitazone) with optically active 1-phenylethylamines. Chem. Pharm. Bull. 1984, 32, 4460-5.
47. Stork, G.; Brizzolara, A.; Landesman, H.; Szmuszkovicz, J.; Terrell, R. The Enamine Alkylation and Acylation of Carbonyl Compounds. J. Am. Chem. Soc. 1963, 85, 207-22.
48. Westheimer, F. H.; Taguchi, K. Catalysis by molecular sieves in the preparation of ketimines and enamines. J. Org. Chem. 1971, 36, 1570-2.
49. Adams, J.; Spero, D. M. Rhodium(II) catalyzed reactions of diazocarbonyl compounds. Tetrahedron 1991, 47, 1765-808.
50. Kawamatsu, Y.; Asakawa, H.; Saraie, T.; Imamiya, E.; Nishikawa, K.; Hamuro, Y. Studies on antihyperlipidemic agents. II. Synthesis and biological activities of 2-chloro-3-arylpropionic acids. Arzneim.-Forsch. 1980, 30, 585-9.
51. Denny, W. A.; Cain, B. F. Potential antitumor agents. 27. Quantitative structure-antileukemic (L1210) activity relationships for the ω[4-(9-acridinylamino)phenyl]alkanoic acids. J. Med. Chem. 1978, 21, 430-7.
52. Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D. M.; Rizzi, J. P. Novel thiazolidine-2,4-diones as potent euglycemic agents. J. Med. Chem. 1992, 35, 1853-64.
53. Horner, M.; Nissen, A. 2-Hydroxyalkylchromans. Ger. Offen., 1981.
54. Doyle, M. P.; Austin, R. E.; Bailey, A. S.; Dwyer, M. P.; Dyatkin, A. B.; Kalinin, A. V.; Kwan, M. M. Y.; Liras, S.; Oalmann, C. J.; et al. Enantioselective Intramolecular Cyclopropanations of Allylic and Homoallylic Diazoacetates and Diazoacetamides Using Chiral Dirhodium(II) Carboxamide Catalysts. J. Am. Chem. Soc. 1995, 117, 5763-75.
55. Doyle, M. P.; Zhou, Q. L.; H., S. S.; Lynch, V. Dirhodium(II) tetrakis[alkyl 2-oxaazetidine-4(S)-carboxylates]. A new set of effective chiral catalysts for asymmetric intermolecular cyclopropanation reactions with diazoacetates. Syn1996, 697-8.
56. Bode, J. W.; Doyle, M. P.; Protopopova, M. N.; Zhou, Q.-L. Intramolecular Regioselective Insertion into Unactivated Prochiral Carbon-Hydrogen Bonds with Diazoacetates of Primary Alcohols Catalyzed by Chiral Dirhodium(II) Carboxamidates. Highly Enantioselective Total Synthesis of Natural Lignan Lactones. J. Org. Chem. 1996, 61, 9146-55.
57. Haigh, D. Heterocyclic compounds and their use in the treatment of type 2 diabetes. PCT Int. Appl., 1993.
58. Brieaddy, L. E.; Donaldson, K. H. The synthesis of cis-6,12-diaryl-6H,12H-dibenzo[b,f][1,5]dithiocin-6,12-imine and cis-6,12-diphenyl-6,12-epoxy-6H,12H-dibenzo[b,f][1,5]dithiocin. J. Heterocycl. Chem. 1995, 32, 1683-6.
59. Ishiyama, T.; Kizaki, H.; Miyaura, N.; Suzuki, A. Synthesis of unsymmetrical biaryl ketones via palladium-catalyzed carbonylative cross-coupling reaction of arylboronic acids with iodoarenes. Tetrahedron Lett. 1993, 34, 7595-8.
60. Nichols, J. S.; Parks, D. J.; Consler, T. G.; Blanchard, S. G. Development of a Scintillation Proximity Assay for Peroxisome Proliferator-Activated Receptor gamma Ligand Binding Domain. Anal. Biochem. 1998, 257, 112-9.
61. Hiragun, A.; Sato, M.; Mitsui, H. Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent. J. Cell. Physiol. 1988, 134, 124-30.
62. Lenhard, J. M.; Kliewer, S. A.; Paulik, M. A.; Plunket, K. D.; Lehmann, J. M.; Weiel, J. E. Effects of troglitazone and metformin on glucose and lipid metabolism. Alterations of two distinct molecular pathways. Biochem. Pharmacol. 1997, 54, 801-8.
63. Shafrir, E. Animal models of noninsulin-dependent diabetes. Diabetes / Metab. Rev. 1992, 8, 179-208.
64. Bailey, C. J.; Flatt, P. R. In Animal Models of Diabetes; Bailey, C. J., Flatt, P. R., Eds.; Churchill Livingstone: Edinburgh, 1986; Vol. 2, pp 71-89.
65. (a) Hu, E.; Kim, J. B.; Sarraf, P.; Spiegelman, B. M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 1996, 274, 2100-3.
66. (b) Adams, M.; Reginato, M. J.; Shao, D.; Lazar, M. A.; Chatterjee, V. K. Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 1997, 272, 5128-32.
67. (c) Zhang, B.; Berger, J.; Zhou, G.; Eibrecht, A.; Biswas, S.; White-Carrington, S.; Szalkowski, D.; Moller, D. E. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor γ. J. Biol. Chem. 1996, 277, 31771-4.
68. (d) Camp, H. S.; Tafuri, S. R. Regulation of peroxisome proliferator-activated receptor γ activity by mitogen-activated protein kinase. J. Biol. Chem. 1997, 272, 10811-16.
69. (a) Puigserver, P.; Wu, Z.; Park, C. W.; Graves, R.; Wright, M.; Spiegelman, B. M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92, 829-9.
70. (b) Zhu, Y.; Qi, C.; Calandra, C.; Rao, M.; Sambasiva, R.; Janardan, K. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor γ. Gene Express. 1996, 6, 185-95.
71. (c) Direnzo, J.; Soderstrom, M.; Kurokawa, R.; Ogliastro, M.-H.; Ricote, M.; Ingrey, S.; Horlein, A.; Rosenfeld, M. G.; Glass, C. K. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol. Cell. Biol. 1997, 17, 2166-76.
72. Brun, R. P.; Kim, J. B.; Hu, E.; Spiegelman, B. M. Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Curr. Opin. Lipidol. 1997, 8, 212-8.
73. Ellingboe, J. W.; Alessi, T. R.; Dolak, T. M.; Nguyen, T. T.; Tomer, J. D.; Guzzo, F.; Bagli, J. F.; McCaleb, M. L. Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides. J. Med. Chem. 1992, 35, 1176-83.
74. Ellingboe, J. W.; Lombardo, L. J.; Alessi, T. R.; Nguyen, T. T.; Guzzo, F.; Guinosso, C. J.; Bullington, J.; Browne, E. N. C.; Bagli, J. F. Antihyperglycemic activity of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides. J. Med. Chem. 1993, 36, 2485-93.
75. Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y. Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy)benzyl]thiazolidine-2,4-dione (AL-321) and related compounds. Chem. Pharm. Bull. 1982, 30, 3563-73.
76. Kees, K. L.; Caggiano, T. J.; Steiner, K. E.; Fitzgerald, J. J., Jr.; Kates, M. J.; Christos, T. E.; Kulishoff, J. M.; Moore, R. D.; McCaleb, M. L. Studies on New Acidic Azoles as Glucose-Lowering Agents in Obese, Diabetic db/db Mice. J. Med. Chem. 1995, 38, 617-28.
77. Kees, K. L.; Fitzgerald, J. J., Jr.; Steiner, K. E.; Mattes, J. F.; Mihan, B.; Tosi, T.; Mondoro, D.; McCaleb, M. L. New Potent Antihyperglycemic Agents in db/db Mice: Synthesis and Structure-Activity Relationship Studies of (4-Substituted benzyl)-(trifluoromethyl)pyrazoles and -pyrazolones. J. Med. Chem. 1996, 39, 3920-8.
78. Dow, R. L.; Bechle, B. M.; Chou, T. T.; Clark, D. A.; Hulin, B.; Stevenson, R. W. Benzyloxazolidine-2,4-diones as potent hypoglycemic agents. J. Med. Chem. 1991, 34, 1538-44.
79. Hulin, B.; Newton, L. S.; Lewis, D. M.; Genereux, P. E.; Gibbs, E. M.; Clark, D. A. Hypoglycemic Activity of a Series of α-Alkylthio and α-Alkoxy Carboxylic Acids Related to Ciglitazone. J. Med. Chem. 1996, 39, 3897-907.
80. (a) Buckle, D. R.; Cantello, B. C. C.; Cawthorne, M. A.; Coyle, P. J.; Dean, D. K.; Faller, A.; Haigh, D.; Hindley, R. M.; Jefcott, L. J.; Lister, C. A.; Pinto, I. L.; Rami, H. K.; Smith, D. G.; Smith, S. A. Nonthiazoliclinedione antihyperglycemic agents. 1: α-Heteroatom substituted β-phenylpropanoic acids. Bioorg. Med. Chem. Lett. 1996, 6, 2121-6.
81. (b) Buckle, D. R.; Cantello, B. C. C.; Cawthorne, M. A.; Coyle, P. J.; Dean, D. K.; Faller, A.; Haigh, D.; Hindley, R. M.; Lefcott, L. J.; Lister, C. A.; Pinto, I. L.; Rami, H. K.; Smith, D. G.; Smith, S. A. Nonthiazolidinedione antihyperglycemic agents. 2: α-Carbon substituted β-phenylpropanoic acids. Bioorg. Med. Chem. Lett. 1996, 6, 2127-30.
82. Young, P. W.; Buckle, D. R.; Cantello, B. C. C.; Chapman, H.; Clapham, J. C.; Coyle, P. J.; Haigh, D.; Hindley, R. M.; Holder, J. C.; Kallender, H.; Latter, A. J.; Lawrie, K. W. M.; Mossakowska, D.; Murphy, G. J.; Cox, L. R.; Smith, S. A. Identification of high-affinity binding sites for the insulin sensitizer Rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for Peroxisomal Proliferator-Activated Receptor γ. J. Pharmacol. Exp. Ther. 1998, 284, 751-9.
83. (a) Naringrekar, V. H.; Stella, V. J. Mechanism of hydrolysis and structure-stability relationship of enaminones as potential prodrugs of model primary amines. J. Pharm. Sci. 1990, 79, 138-46.
84. (b) Larsen, J. D.; Bundgaard, H. Prodrugs as drug delivery systems. 49. Hydrolysis kinetics of enaminones derived from various amino acids and 1,3-diketones, keto-esters and keto-amides. Arch. Pharm. Chem., Sci. Ed. 1986, 14, 52-63.
85. Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. J. Med. Chem. 1992, 35, 2617-26.
86. X-ray crystallographic analysis of ligands from each series cocrystallized with the ligand binding domain of hPPARγ indicates that the carboxylic acid moiety of the N-(2-benzoylphenyl)tyrosines and the 2,4-thiazolidinedione moiety of the TZDs interact with the same portion of the ligand binding domain in the hPPARγ receptor, with the benzophenone occupying a pocket which remains empty in the PPARγ-TZD complex (M. Milburn, unpublished results from these laboratories).
87. Brown, K. K.; Henke, B. R.; Blanchard, S. G.; Cobb, J. E.; Kaldor, I.; Kliewer, S. A.; Lehmann, J. M.; Lenhard, J. M.; Harrington, W.; Novak, P. J.; Binz, J.; Hashim, M. A.; Oliver, W. O.; Brown, H. R.; Parks, D. J.; Plunket, K. D.; Tong, T.; Menius, A.; Adkison, K. K.; Noble, S. A.; Willson, T. M. Novel N-aryl tyrosine activators of PPARγ reverse the diabetic phenotype of the zucker diabetic fatty rat. Diabetes, submitted for publication.
88. Kumar, S.; Boulton, A. J. M.; Beck-Nielsen, H.; Berthezene, F.; Muggeo, M.; Persson, B.; Spinas, G. A.; Donoghue, S.; Lettis, S.; Stewart-Long, P. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996, 39, 701-709.
89. For an excellent discussion on the possible downstream mechanism of action of PPARγ activators, see: Spiegelman, B. M. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47, 507-4.